Quintiles opens new European headquarters in the UK
pharmafile | October 12, 2011 | News story | Research and Development | Quintiles, research and development news
Pharmaceutical services company Quintiles has opened a new European headquarters in the UK.
The Reading, Berkshire facility will house more than 500 employees who will relocate from three separate offices to the new state-of-the-art space.
At the opening ceremony Quintiles founder, chairman and chief executive Dennis Gillings, CBE, stressed the continued importance of Europe, and particularly the UK, in the global phamra market.
“I am proud to extend our strategic commitment to Europe, Middle East and Africa with this regional headquarters investment. With such a wealth of scientific, medical and commercial expertise in the UK, the move has encouraged more cross-discipline collaboration to better serve Quintiles’ customers and power them forward in the fast-morphing world of biopharma.”
Quintiles employs over 9,000 people across Europe, Middle East and Africa, more than 2,000 of which are based in the UK.
Lord Howe, Parliamentary Under-Secretary of State for Health, commented: “Having Quintiles open their European headquarters in Reading is excellent news. Their decision shows that the UK is an attractive environment for international pharmaceutical companies to invest in.
“The Government is committed to promoting the development of new, innovative treatments for NHS patients and I look forward to seeing the results of the exciting work that Quintiles will carry out at Reading.”
The company has been investing steadily in the UK, opening a laboratory and office facility in Edinburgh, Scotland in 2009 and the expanding its Phase I facility in London in March 2010.
More recently the company opened its first ‘prime site’ clinical research facility at Queen Mary, University of London in July this year.
Dominic Tyer
Related Content
Quintiles to merge with IMS Health
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement …
Contract research news in brief
Icon offers $52m for CCH’s clinical services division, plus updates from PPD, Aptuit, Argenta, Quintiles …
Contract research news in brief
Synteract agrees to by Harrison Clinical Research, WuXi forges JV with PR, plus appointments and …
